Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$0.65 -6.9%	$0.63	$0.51 ▼ $2.92	$26.64M	-0.4	17,214 shs	643,146 shs
CELU Celularity	$0.87 -12.3%	$1.07	$0.71 ▼ $4.35	$25.25M	0.48	154,450 shs	34,202 shs
CRVO CervoMed	$2.94 -5.8%	$3.62	$2.82 ▼ $13.13	$27.22M	-0.68	68,073 shs	62,170 shs
GNPX Genprex	$0.65 -6.9%	$1.06	$0.63 ▼ $55.00	$6.85M	-0.98	238,469 shs	393,034 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	-4.52%	-2.67%	+8.14%	-35.44%
CELU Celularity	0.00%	-13.63%	-3.88%	-27.91%	-57.66%
CRVO CervoMed	0.00%	-5.47%	-22.63%	-28.47%	-60.70%
GNPX Genprex	0.00%	-17.04%	-25.24%	-66.84%	-95.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$0.65 -6.9%	$0.63	$0.51 ▼ $2.92	$26.64M	-0.4	17,214 shs	643,146 shs
CELU Celularity	$0.87 -12.3%	$1.07	$0.71 ▼ $4.35	$25.25M	0.48	154,450 shs	34,202 shs
CRVO CervoMed	$2.94 -5.8%	$3.62	$2.82 ▼ $13.13	$27.22M	-0.68	68,073 shs	62,170 shs
GNPX Genprex	$0.65 -6.9%	$1.06	$0.63 ▼ $55.00	$6.85M	-0.98	238,469 shs	393,034 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	-4.52%	-2.67%	+8.14%	-35.44%
CELU Celularity	0.00%	-13.63%	-3.88%	-27.91%	-57.66%
CRVO CervoMed	0.00%	-5.47%	-22.63%	-28.47%	-60.70%
GNPX Genprex	0.00%	-17.04%	-25.24%	-66.84%	-95.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRNS Barinthus Biotherapeutics	2.00	Hold	$4.00	513.40% Upside
CELU Celularity	2.00	Hold	$6.00	587.84% Upside
CRVO CervoMed	2.63	Moderate Buy	$22.60	668.71% Upside
GNPX Genprex	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest GNPX, CELU, CRVO, and BRNS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/18/2026	CRVO CervoMed	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$9.00
5/8/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
4/23/2026	CRVO CervoMed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
4/22/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
4/22/2026	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$31.00
4/21/2026	GNPX Genprex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
4/20/2026	CRVO CervoMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
4/8/2026	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$31.00
3/18/2026	CRVO CervoMed	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$19.00 ➝ $11.00
3/18/2026	CRVO CervoMed	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$15.00 ➝ $21.00

(Data available from 6/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRNS Barinthus Biotherapeutics	$14.97M	1.78	N/A	N/A	$1.82 per share	0.36
CELU Celularity	$26.55M	0.95	N/A	N/A	($1.32) per share	-0.66
CRVO CervoMed	$4.01M	6.79	N/A	N/A	$1.97 per share	1.49
GNPX Genprex	N/A	N/A	N/A	N/A	$2.42 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRNS Barinthus Biotherapeutics	-$66.43M	-$1.29	N/A	N/A	N/A	N/A	-63.83%	-48.77%	8/6/2026 (Estimated)
CELU Celularity	-$91.72M	-$3.33	N/A	N/A	N/A	-345.45%	N/A	-77.94%	8/12/2026 (Estimated)
CRVO CervoMed	-$26.97M	-$3.28	N/A	N/A	N/A	-672.80%	-136.08%	-112.62%	8/14/2026 (Estimated)
GNPX Genprex	-$16.23M	-$14.14	N/A	N/A	N/A	N/A	-247.32%	-176.73%	N/A

Latest GNPX, CELU, CRVO, and BRNS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/18/2026	Q1 2026	CRVO CervoMed	-$0.90	-$0.86	+$0.04	-$0.86	$0.07 million	N/A
5/13/2026	Q1 2026	GNPX Genprex	N/A	-$0.64	N/A	-$0.64	N/A	N/A
4/30/2026	Q1 2026	BRNS Barinthus Biotherapeutics	-$0.28	-$0.14	+$0.14	-$0.14	N/A	N/A
4/30/2026	Q4 2025	CELU Celularity	N/A	-$0.85	N/A	-$0.85	N/A	$4.10 million
3/13/2026	Q4 2025	BRNS Barinthus Biotherapeutics	-$0.40	-$0.27	+$0.13	-$0.27	N/A	N/A
3/13/2026	Q4 2025	CRVO CervoMed	-$0.79	-$0.88	-$0.09	-$0.88	$0.84 million	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CELU Celularity	N/A	N/A	N/A	N/A	N/A
CRVO CervoMed	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRNS Barinthus Biotherapeutics	N/A	6.05	6.05
CELU Celularity	N/A	0.15	0.15
CRVO CervoMed	N/A	3.36	3.36
GNPX Genprex	N/A	5.61	5.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRNS Barinthus Biotherapeutics	25.20%
CELU Celularity	19.02%
CRVO CervoMed	25.15%
GNPX Genprex	14.05%

Insider Ownership

Company	Insider Ownership
BRNS Barinthus Biotherapeutics	10.70%
CELU Celularity	17.30%
CRVO CervoMed	35.40%
GNPX Genprex	0.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRNS Barinthus Biotherapeutics	107	40.85 million	36.48 million	N/A
CELU Celularity	220	28.95 million	23.94 million	Optionable
CRVO CervoMed	4	9.26 million	5.98 million	Not Optionable
GNPX Genprex	20	10.59 million	10.56 million	No Data

GNPX, CELU, CRVO, and BRNS Headlines

Recent News About These Companies

Genprex Highlights Biomarker Data for Reqorsa Lung Cancer Therapy

May 26, 2026 | tipranks.com

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

May 26, 2026 | prnewswire.com

GNPX Share News Today

May 15, 2026 | uk.investing.com

Genprex Announces Positive Preclinical Data for Diabetes Gene Therapy

May 14, 2026 | tipranks.com

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

May 14, 2026 | prnewswire.com

Genprex Expands Reqorsa Cancer Therapy Patent Protection in Israel

April 30, 2026 | tipranks.com

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

April 30, 2026 | prnewswire.com

Genprex Highlights Promising Preclinical Data for Diabetes Gene Therapy

April 28, 2026 | tipranks.com

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

April 28, 2026 | prnewswire.com

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

April 22, 2026 | prnewswire.com

Genprex Expands Lung Cancer Gene Therapy Research Collaboration

April 21, 2026 | tipranks.com

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy

April 21, 2026 | prnewswire.com

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

April 20, 2026 | prnewswire.com

Genprex Insider Trading Activity | NASDAQ:GNPX | Benzinga

April 3, 2026 | benzinga.com

Genprex Inc.

March 19, 2026 | barrons.com

Genprex Highlights New Reqorsa Preclinical Data at AACR

March 18, 2026 | tipranks.com

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

March 18, 2026 | prnewswire.com

Genprex to Participate at BIO Europe Spring 2026

March 10, 2026 | prnewswire.com

Genprex, Inc.: Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa Gene Therapy in Combination with Immunotherapies to Treat Cancer

February 23, 2026 | finanznachrichten.de

Genprex stock jumps on Japan, Europe patent approvals

February 23, 2026 | za.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX, CELU, CRVO, and BRNS Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

$0.65 -0.05 (-6.95%)

Closing price 06/5/2026 03:59 PM Eastern

Extended Trading

$0.60 -0.06 (-8.60%)

As of 06/5/2026 07:49 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Celularity NASDAQ:CELU

$0.87 -0.12 (-12.33%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$0.86 -0.01 (-1.07%)

As of 06/5/2026 07:51 PM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

CervoMed NASDAQ:CRVO

$2.94 -0.18 (-5.77%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$2.94 0.00 (-0.17%)

As of 06/5/2026 05:11 PM Eastern

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Genprex NASDAQ:GNPX

$0.65 -0.05 (-6.95%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$0.65 +0.01 (+1.13%)

As of 06/5/2026 07:56 PM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNPX, CELU, CRVO, and BRNS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNPX, CELU, CRVO, and BRNS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNPX, CELU, CRVO, and BRNS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX, CELU, CRVO, and BRNS Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

Celularity NASDAQ:CELU

CervoMed NASDAQ:CRVO

Genprex NASDAQ:GNPX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GNPX, CELU, CRVO, and BRNS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GNPX, CELU, CRVO, and BRNS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GNPX, CELU, CRVO, and BRNS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX, CELU, CRVO, and BRNS Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

Celularity NASDAQ:CELU

CervoMed NASDAQ:CRVO

Genprex NASDAQ:GNPX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools